WHY MEET AGENDIA AT ESMO 2026?
Genomic insights for better decisions
in early-stage breast cancer
NEW DATA TO BE PRESENTED
New MammaPrint + BluePrint Data at the ESMO Congress 2026
ABOUT
About the ESMO Congress 2026
The ESMO Congress 2026, hosted by the European Society for Medical Oncology (ESMO), will bring the global oncology community to Madrid, Spain, October 23–27, 2026. Held at IFEMA MADRID, the congress will showcase advances in cancer research, clinical practice, precision oncology, and patient care, bringing together oncologists, researchers, patient advocates, and healthcare leaders from around the world.
Visit Agendia at Booth #8041 to learn how MammaPrint® and BluePrint® genomic testing provide insights into recurrence risk and tumor biology to help inform personalized treatment decisions for patients with early-stage breast cancer. Connect with our team to explore the latest evidence and discuss how genomic insights can help guide breast cancer treatment planning.
This landing page is independently managed by Agendia and is not officially sponsored, endorsed, or affiliated with ESMO.
THE MAMMAPRINT + BLUEPRINT TEST SUITE
Analyze over a hundred relevant genes at once.
With the additional results of BluePrint, our molecular subtyping test, physicians gain an even broader genomic profile. From just one tumor block, you can interrogate over 150 genes containing information on a tumor’s level of aggression and potential for growth. These insights will serve as an essential resource for guiding your pre- and post-operative treatment strategies.
